Comments on: U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies

Comments on: U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies https://www.worldpharmatoday.com/press-releases/us-food-and-drug-administration-accepts-for-priority-review-the-biologics-license-application-for-empliciti-elotuzumab-for-the-treatment-of-multiple-myeloma-in-patients-who-have-received-one-or-more-p/ Magazine for the C-level Pharma Executives Wed, 26 Aug 2015 18:30:00 +0000 hourly 1 https://wordpress.org/?v=6.9.4